# Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

> **NCT01399593** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 102 (actual)

## Conditions studied

- Antibody Mediated Rejection

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT01399593
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11-02
- **Primary completion:** 2014-05-13
- **Final completion:** 2015-11-13
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** Did not achieve statistical significance for primary endpoint
- **Last updated:** 2017-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01399593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01399593, "Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01399593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*